Does exercise relieve vasomotor menopausal symptoms? by Lyon, Corey et al.
Evidence-based answers from the  
Family Physicians Inquiries Network
175MDEDGE.COM/JFPONLINE VOL 67, NO 3  |  MARCH 2018  |  THE JOURNAL OF FAMILY PRACTICE
CLINICAL INQUIRIES
EVIDENCE-BASED ANSWER
A
Corey Lyon, DO; Rebecca 
Mullen, MD; Brandy  
Deffenbacher, MD; Alex 
Reed, PhD 
University of Colorado 
Family Medicine Residency, 
Denver
Joan Nashelsky, MLS
Family Physicians Inquiries 
Network, Iowa City
DEPUTY EDITOR
Rick Guthmann, MD, 
MPH
Advocate Illinois Masonic 
Family Medicine Residency, 
Chicago 
Q Does exercise relieve  
vasomotor menopausal  
symptoms?
 NO. Exercise doesn’t decrease 
 the frequency or severity of vaso-
motor menopausal symptoms (VMS) in 
perimenopausal and postmenopausal 
women (strength of recommendation: 
A, systematic review of randomized con-
trolled trials [RCTs] and consistent RCT). 
Evidence summary
A 2014 Cochrane meta-analysis of 5 RCTs with 
a total of 733 patients examined the effective-
ness of any type of exercise in decreasing va-
somotor symptoms in perimenopausal and 
postmenopausal women.1 The studies com-
pared exercise—defined as structured exercise 
or physical activity through active living—with 
no active treatment, yoga, or hormone therapy 
(HT) over a 3- to 24-month follow-up period.  
Three trials of 454 women that compared 
exercise with no active treatment found no dif-
ference between groups in frequency or inten-
sity of vasomotor symptoms (standard mean 
difference [SMD]= -0.10; 95% confidence in-
terval [CI], -0.33 to 0.13). 
Two trials with 279 women that compared 
exercise with yoga didn’t find a difference in 
reported frequency or intensity of vasomotor 
symptoms between the groups (SMD= -0.03; 
95% CI, -0.45 to 0.38). 
One small trial (14 women) of exercise 
and HT found that HT patients reported de-
creased frequency of flushes over 24 hours 
compared with the exercise group (mean dif-
ference [MD]=5.8; 95% CI, 3.17-8.43). 
Overall, the evidence was of low quality 
because of heterogeneity in study design.1 
Two exercise interventions  
fail to reduce symptoms
A 2014 RCT, published after the Cochrane 
search date, investigated exercise as a treat-
ment for VMS in 261 perimenopausal and 
postmenopausal women ages 48 to 57 years.2 
Patients had a history of at least 5 hot flashes 
or night sweats per day and hadn’t taken HT 
in the previous 3 months. 
The women were randomized to one of 
2 exercise interventions or a control group. 
The exercise interventions both entailed 
2 one-on-one consultations with a physical 
activity facilitator and use of a pedometer. 
Patients were encouraged to perform 30 min-
utes of moderate-intensity exercise 3 days 
a week during Weeks 1 through 12, then in-
crease the frequency to 3 to 5 days a week 
during Weeks 13 through 24. In one interven-
tion arm, the women also received an infor-
mational DVD and 5 educational leaflets. 
In the other arm, they were invited to at-
tend 3 exercise support groups in their local 
community. The control group was offered 
an opportunity for exercise consultation and 
given a pedometer at the end of the study. 
At the end of the 6-month intervention, 
neither exercise intervention significantly 
decreased self-reported hot flashes/night 
sweats per week compared with the con-
trol group (DVD exercise arm vs control: 
MD= -8.9; 95% CI, -20 to 2.2; social support 
exercise arm vs control: MD= -5.2; 95% CI, 
-16.7 to 6.3). The study also found no differ-
ence in hot flashes/night sweats per week at 
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12-month follow-up between the DVD ex-
ercise arm and controls (MD= -3.2; 95% CI, 
-12.7 to 6.4) and the social-support group and 
controls (MD= -3.5; 95% CI, -13.2 to 6.1).
Drug therapy relieves symptoms,  
but other methods—not so much
An analysis of pooled individual data from 
3 RCTs compared exercise with 5 other in-
terventions for VMS in 899 perimenopausal 
and postmenopausal women.3 Patients had 
at least 14 bothersome symptoms per week. 
The 6 interventions ranged from non-
pharmacologic therapies, such as aerobic 
exercise and yoga, to pharmacologic treat-
ments, including escitalopram 10 to 20 mg/d, 
venlafaxine 75 mg/d, oral estradiol (E2) 
0.5 mg/d, and omega-3 supplementation 
1.8 g/d. The primary outcome was a change 
in VMS frequency and bother as assessed 
by a symptom diary over the 4- to 12-week 
follow-up. 
The analysis found a significant 6-week 
reduction in daily VMS frequency relative to 
placebo for escitalopram (MD= -1.4; 95% CI, 
-2.7 to -0.2), low-dose E2 (MD= -1.9; 95% CI, 
-2.9 to -0.9), and venlafaxine (MD= -1.3; 95% 
CI, -2.3 to -0.3). However, no difference in VMS 
frequency or bother was found with exercise 
(MD= -0.4; 95% CI, -1.1 to 0.3), yoga (MD= -0.6; 
95% CI, -1.3 to 0.1), or omega-3 supplementa-
tion (MD= 0.2; 95% CI, -0.4 to 0.8).
Recommendations
The American College of Obstetricians and 
Gynecologists (ACOG) doesn’t offer spe-
cific recommendations regarding exercise 
as a treatment for symptoms of menopause. 
The 2014 ACOG guidelines for managing 
symptoms report that data don’t support 
phytoestrogens, supplements, or lifestyle 
modifications (Level B, based on limited or 
inconsistent evidence). ACOG recommends 
basic palliative measures such as drinking 
cool drinks and decreasing layers of clothing 
(Level B).4 
The American Association of Clinical 
Endocrinologists’ recommendations don’t 
mention exercise as a menopause therapy.5 
The North American Menopause Soci-
ety’s 2015 statement regarding the nonhor-
monal treatment of menopause symptoms 
doesn’t recommend exercise as an effective 
therapy because of insufficient or inconclu-
sive data.6                           JFP
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